Body Weight, Body Weight Changes, Diabetes Mellitus, Diabetes Mellitus, Type 2, PreDiabetes
Conditions
Brief summary
A large body of research has demonstrated that intensive lifestyle interventions and metformin are effective treatments to prevent or delay diabetes among high-risk adults, yet neither treatment is routinely used in practice. This pilot study will develop and evaluate the Diabetes Risk Education and Communication Trial (DiRECT) intervention, which communicates information about diabetes risk and treatment options for preventing diabetes among primary care patients with prediabetes. Given that 38% of U.S. adults have prediabetes, this project has large potential to impact public health by developing a scalable intervention to promote the use of evidence-based treatments that lower diabetes risk in this population.
Detailed description
Landmark clinical trials have found that intensive lifestyle interventions (ILI) and metformin are safe and effective treatment options for preventing diabetes among adults with prediabetes and overweight/obesity. Despite being included in expert clinical guidelines, these treatments are rarely used in practice and little existing research has focused on approaches for promoting their use. This novel intervention, delivered by medical assistants before patients' routinely scheduled office visits, consists of the following 3 components intended to promote initiation of ILI and metformin: 1) a prediabetes decision aid focused on diabetes risk and treatment options for preventing diabetes; 2) a think aloud exercise; and 3) formulating a preliminary treatment plan. Previous studies report that medical assistants can improve uptake of some preventive health services in primary care, which may also be true for ILI and metformin.
Interventions
BEHAVIORALDiRECT
DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
BEHAVIORALUsual care (UC)
Standard care with routine medical care.
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Northwestern University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Overweight or obesity * documentation of prediabetes in medical chart or * A1c 5.7-6.4
Exclusion criteria
* Age \< 18; individuals who are not yet adults (infants, children, teenagers) * Patient's primary care physician did not provide permission to participate in the study * Pregnancy status: current or planned pregnancy during study period * Serum creatinine \>1.4mg/dL in women and \>1.5mg/dL in men * Patients that are blind, deaf, or otherwise unable to review study materials * Prior diagnosis of diabetes mellitus type 1 or type 2 or on antidiabetic medication * Diagnosis of post-surgical hypoinsulinemia * Diagnosis of dementia * Uncontrolled hypertension (≥160/100 mm Hg) * No office visit in past 12 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intent to treat questionnaire: Participant initiation of treatment to intensive lifestyle (ILI) or Metformin | 3 months | The number of participants that initiate ILI, Metformin, or both treatments at follow-up is the primary outcome of the pilot trial, which will be assessed in the following ways. Because initiation of metformin requires a provider prescription, this will be assessed pragmatically using the electronic health record (EHR) and confirmed by participant self-report of taking at least 1 dose. Attendance logs will be used to confirm whether participants attended at least 1 ILI session. Those who received a prescription for metformin but do not take any doses will not be considered to have initiated treatment. Similarly, those who are referred to ILI but do not attend any sessions will not be classified as initiating treatment. Receiving a provider's prescription for metformin or referral for ILI without initiating treatment will be an exploratory outcome. |
Countries
United States
Outcome results
None listed